RNAi therapies to target the cause of disease
We are developing a pipeline of RNAi therapies that aim to restore health by addressing the underlying cause of disease. We strive to deliver life-changing therapies as efficiently as possible to meet the urgent needs of individuals living with rare diseases and common diseases that have a genetic component.
Key core programs
Nedosiran (DCR-PHXC) is the only investigational RNAi therapy in development for treatment of all three known genetic types of primary hyperoxaluria (PH).
DCR-HBVS is in development with Roche for treatment of chronic hepatitis B virus (HBV) infection in adults. Unlike current therapies that typically provide long-term suppression, DCR-HBVS has the potential to help cure HBV.
DCR-A1AT is in development for treatment of alpha-1 antitrypsin (A1AT) deficiency-associated liver disease.
